Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital
© Jung et al; licensee BioMed Central Ltd. 2011
Received: 4 November 2010
Accepted: 11 March 2011
Published: 11 March 2011
Healthcare-associated pneumonia (HCAP) has more similarities to nosocomial pneumonia than to community-acquired pneumonia (CAP). However, there have only been a few epidemiological studies of HCAP in South Korea. We aimed to determine the differences between HCAP and CAP in terms of clinical features, pathogens, and outcomes, and to clarify approaches for initial antibiotic management.
We conducted a retrospective, observational study of 527 patients with HCAP or CAP who were hospitalized at Severance Hospital in South Korea between January and December 2008.
Of these patients, 231 (43.8%) had HCAP, and 296 (56.2%) had CAP. Potentially drug-resistant (PDR) bacteria were more frequently isolated in HCAP than CAP (12.6% vs. 4.7%; P = 0.001), especially in the low-risk group of the PSI classes (41.2% vs. 13.9%; P = 0.027). In-hospital mortality was higher for HCAP than CAP patients (28.1% vs. 10.8%, P < 0.001), especially in the low-risk group of PSI classes (16.4% vs. 3.1%; P = 0.001). Moreover, tube feeding and prior hospitalization with antibiotic treatment within 90 days of pneumonia onset were significant risk factors for PDR pathogens, with odds ratios of 14.94 (95% CI 4.62-48.31; P < 0.001) and 2.68 (95% CI 1.32-5.46; P = 0.007), respectively.
For HCAP patients with different backgrounds, various pathogens and antibiotic resistance of should be considered, and careful selection of patients requiring broad-spectrum antibiotics is important when physicians start initial antibiotic treatments.
Pneumonia has traditionally been classified as either community- or hospital- acquired, based on the patient's location when the infection was acquired. However, an increasing number of out-of-hospital services, such as nursing homes, outpatient parenteral therapy, hemodialysis clinics, and domiciliary care, create a class of patients who do not truly reside in the "community."
Previous studies have suggested that nursing home-acquired pneumonia or pneumonia in long-term care facilities should be considered separately from community-acquired pneumonia (CAP) [1–3]. Infections occurring in these patients show a more similar epidemiological pattern to hospital-acquired pneumonia (HAP) than to CAP [1–3]. Different epidemiological patterns from CAP require a distinct targeted therapeutic approach, especially against multidrug-resistant pathogens [4, 5]. Thus, since 2000, the newly published CAP guidelines have recommended management specific to this type of pneumonia, and considered it to be a separate entity from CAP [6–8].
In 2005, the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) documented healthcare-associated pneumonia (HCAP) as a new category of pneumonia . However, only a few studies on HCAP have included patients who met the criteria of the 2005 ATS/IDSA guidelines. Previous HCAP studies have revealed a diverse composition of participants because this new HCAP category includes various criteria for heterogeneous conditions, such as nursing home residence, previous antibiotic therapy, or regular attendance at a dialysis clinic [11–13]. Since the criteria for defining HCAP have not been standardized between these studies, and due to the existence of geographically different etiologies, more data are required for a better characterization of unified HCAP and for redefining HCAP.
In South Korea, there are limited data and no therapeutic guidelines focusing on HCAP . Considering the relatively small proportion of long-term care facilities and the different antibiotic resistance patterns of the microorganisms in CAP, the clinical composition, causative pathogens, and clinical outcomes of HCAP in South Korea could be different from those in other countries. Therefore, a study evaluating HCAP characteristics and clinical outcomes in South Korea is needed.
The aim of this study was to categorize patients according to the 2005 ATS/IDSA guidelines, to determine differences in baseline characteristics, pathogens, and clinical outcomes between patients with HCAP and CAP in a university teaching hospital in South Korea, and to clarify approaches for initial antibiotic management.
Study design and subjects
We conducted a retrospective observational study of 527 patients with CAP or HCAP who were hospitalized at Severance Hospital (a 2,000-bed university tertiary referral hospital in Seoul, South Korea) between January 1 and December 31, 2008. Patients were classified into either a CAP or HCAP group, according to the 2005 ATS/IDSA guidelines. We compared baseline characteristics, and identified pathogens, antibiotics regimens, and clinical outcomes between the two groups. The study protocol was approved by the Ethical Review Committee of Severance Hospital.
Pneumonia was defined as the presence of a new infiltrate on the chest radiography plus at least one of the following: fever (temperature ≥ 38.0°C) or hypothermia (temperature < 35.0°C), new cough with or without sputum production, pleuritic chest pain, dyspnea, or altered breath sounds on auscultation .
HCAP included any patient who fulfilled any of the following: (1) hospitalization in an acute care hospital for two or more days within 90 days of the infection; (2) residence in a nursing home or long-term care facility; (3) infusion therapy, such as intravenous antibiotic therapy, chemotherapy or wound care, within 30 days of a current infection; (4) regular attendance at a dialysis clinic, including hemodialysis and peritoneal dialysis . CAP included any patient with pneumonia who did not meet the HCAP criteria.
Patients were defined as being immunosuppressed if they fulfilled at least one of the following criteria: (1) daily administration of systemic corticosteroids (at least 15 mg of prednisone per day for more than one month or combination therapy with low dose corticosteroids and other immunosuppressants including azathioprine, mycophenolate, methotrexate, cyclosporine, or cyclophosphamide) (2) seropositivity for human immunodeficiency virus; (3) receipt of either a solid organ or bone marrow transplant; (4) treatment with radiation therapy or chemotherapy for an underlying malignancy during the 6 months prior to hospital admission; or (5) underlying acquired immune deficiency disorder [11, 13].
In this study, potentially drug resistant (PDR) pathogens included methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinetobacter baumannii, Stenotrophomonas maltophilia, and extended spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, based on previous reports showing problematic clinical outcomes for infections caused by these pathogens [16, 17].
The definition of early treatment failure was clinical deterioration within 72 hours of starting treatment, such as a lack of response or worsening of fever, respiratory condition, and/or radiographic status, requiring mechanical ventilation or aggressive fluid resuscitation or vasopressors, or death [12, 18, 19].
The severity of pneumonia was evaluated and categorized using the validated prediction rule and pneumonia severity index (PSI) scores: low, class I to III; intermediate, class IV; high, class V [20, 21].
Antibiotic therapy was initiated in basic accordance with the ATS/IDSA guidelines (8,9), but the detailed antibiotic regimen complied with the attending physician's choice taking into consideration patient risk factors and the severity of the disease. Empirical antibiotic therapy was modulated after the pathogen was identified according to the susceptibility test. However, the antibiotic therapy was changed or extended according to the attending physician's decision for patients in whom the pathogen was not identified or whose clinical condition deteriorated.
Pathogens in samples obtained from sputum, blood, or other samples were investigated using standard microbiological procedures. Blood cultures were accepted as an etiological diagnosis if no other source could be identified for the positive blood culture. Sputum samples were cultured in a semi-quantitative manner, and an etiological diagnosis was established when a predominant microorganism was isolated from group 4 or 5 sputum, according to Murray and Washington's grading system . A rapid immunochromatographic assay was used for detecting the Streptococcus pneumoniae antigen (BinaxNOW® S. pneumoniae Test; Binax Inc., Scarborough, ME, USA) and Legionella pneumophila serogroup I antigen (BinaxNOW® Legionella Test; Binax Inc., Scarborough, ME, USA) in urine. Antibodies against atypical pathogens (Mycoplasma pneumoniae) were detected by microparticle agglutination assay (MAG). Cases that did not meet any of these criteria were considered to be pneumonia of unknown etiology. The antibiotic sensitivity of all isolates was determined using a disc diffusion method, according to the Clinical and Laboratory Standards Institute guidelines .
Categorical variables were analyzed using the χ2 test or Fisher's exact test, and continuous variables were analyzed using Student's t-test or Mann-Whitney U test. After testing the distribution of continuous variables, normally distributed variables were presented as mean ± standard deviation (SD) and non-normally distributed variables were presented as median (interquartile range, [IQRs]). Multivariate analysis was performed using a logistic regression model to estimate risk factors for occurrence of PDR pathogens, which was presented with the odds ratio (OR, 95% confidence intervals, CI). Potential candidate variables were those with P < 0.05 in univariate analyses, and the multi-collinearity of variables was checked. All tests were two-sided and a P-value < 0.05 was deemed to be statistically significant. SPSS 18.0 (SPSS, Chicago, IL, USA) was used for all statistical analyses.
Baseline Characteristics of Patients with HCAP and CAPa
HCAP (n = 231)
(n = 296)
63.5 ± 13.1
65.4 ± 15.7
Chronic lung diseaseb
Central nervous system disorders
Solid organ malignancy
Septic shock at onset
PaO2 < 60 mmHg, SpO2 < 90%, or PaO2/FiO2 < 300
Acute renal failure at onset
pH < 7.35
Hematocrit < 30%
Glucose > 250 mg/dL
Blood urea nitrogen > 30 mg/dL
12790 ± 13603
13175 ± 7519
C-reactive protein (mg/dL)
15.4 ± 11.2
13.1 ± 10.0
Erythrocyte Sedimentation Rate (mm)
83.2 ± 33.8
71.4 ± 35.7
Eastern Cooperative Oncology
1.7 ± 0.9
1.2 ± 0.9
Prior antibiotics use
Pneumonia Severity Index Risk Classes
113.7 ± 32.3
92.2 ± 33.6
Pathogen Distribution in Patients with HCAP and CAPa
HCAP (n= 231)
CAP (n= 296)
ESBL producing c
Atypical pathogens f
Antibiotic treatment and clinical outcomes
Antibiotic Treatments and Clinical Outcomes in Patients with HCAP and CAPa
Inappropriate antibiotic therapy b
β-lactams + fluoroquinolone
β-lactams + macrolide
β-lactams + clindamycin
β-lactams + aminoglycoside
Fluoroquinolone + clindamycin
Antipseudomonal β-lactams + fluroquinolone
Antipseudomonal β-lactams + macrolide
Antipseudomonal β-lactams + clindamycin
Antipseudomonal β-lactams + aminoglycoside
Other combination therapyc
Early treatment failured
Need for mechanical ventilation
Duration of hospital stay (days)
18.6 ± 19.1
12.9 ± 13.1
Occurrence of PDR pathogens and clinical outcomes and in each severity class assessed by PSI
Occurrence of PDR Pathogens and Clinical Outcomes and in Each Severity Class Assessed by the Pneumonia Severity Index in Patients
Pneumonia Severity Index Classes
Early treatment failure b
In-hospital mortality b
Risk Factors for Occurrence of PDR Pathogens
Multivariate Analysis of Risk Factors for Occurrence of PDR Pathogens
0.75 - 3.01
0.98 - 1.02
4.62 - 48.31
Residence in a nursing home or extended care facility
0.53 - 6.86
Intravenous chemotherapy within 30 days
0.22 - 1.77
Attended a hemodialysis clinic
0.86 - 9.19
Hospitalized in an acute care hospital for two or more days within 90 days of the infection
1.32 - 5.46
This study showed that half of the hospitalized patients with pneumonia in a university tertiary referral hospital in South Korea were diagnosed with HCAP, and identified differences in comorbidities, pathogens, initial antibiotic regimens, and clinical outcomes between the HCAP and CAP groups. Moreover, tube feeding and prior hospitalization with antibiotic treatment within 90 days of pneumonia were found to be significant risk factors for PDR pathogens.
Patients with HCAP were more frequently classified into the intermediate- and high-risk classes than patients with CAP. More PDR pathogens were identified, more inappropriate antibiotic treatments were initiated, and clinical outcomes were worse for HCAP patients, especially those in the low and intermediate risk classes. The results of this study were consistent with those of previous studies reporting distinct clinical characteristics of HCAP and worse outcomes than CAP [10, 12, 14, 24]. However, the baseline characteristics and the backgrounds of patients with HCAP differed slightly from previous reports. In this study, more patients with HCAP had malignancies (67.5%) and an immunosuppressive condition (61.5%) as comorbidity than other studies (14.2% to 22.3%) [12, 24]. Furthermore, the HCAP group included a relatively lower proportion of patients residing in nursing homes or extended care facilities (9.1%) than previous reports (28.0% to 61.0%)[12, 24]. These differences indicate the heterogeneous aspect of HCAP and the difficulty of establishing one unified approach for patients with HCAP .
Despite the high rate of anti-pseudomonal therapy in HCAP patients, a high proportion of inappropriate initial antibiotics were given to the patients in this study (37.0%), as compared with the studies of Shindo et al. (20.8%), Carratalà et al. (5.6%), and Park et al. (24.6%) [10, 12, 14]. This is likely due to the higher rate of PDR pathogen infection (36.7%), as compared with the aforementioned reports of Shindo et al. (22.1%), Carratalà et al. (3.5%), and Park et al. (29.3%) in HCAP patients, and the relatively high proportion of ESBL-producing Gram-negative pathogens [10, 12, 14]. In this study, K. pneumoniae (10.0%) was the most common pathogen in patients with HCAP, followed by S. aureus (5.6%), S. pneumoniae (4.8%), and P. aeruginosa (4.3%) in that order. In addition, the rate of ESBL-producing K. pneumoniae was relatively high in our study. This may be explained by differences in the underlying comorbidities of HCAP patients and their reasons for being in contact with the healthcare environment. A large proportion of patients with malignancies who had been regularly hospitalized for anti-cancer chemotherapy and a considerable proportion of patients with recent antibiotic therapy (42.0%) could explain an increasing colonization of ESBL-producing K. pneumoniae. In a report by Park et al., another study done in a tertiary hospital of South Korea, K. pneumoniae is also the second most common pathogen of HCAP and the rate of ESBL-producing K. pneumoniae comes to 79% in both CAP and HCAP . Thus, efforts to identify the pathogens and to adjust empirical antibiotics accordingly, based on microbiological data, are more useful than automatic treatment with anti-pseudomonal broad-spectrum antibiotics.
Negative clinical outcomes, including early treatment failure and in-hospital mortality were all higher in HCAP patients than CAP patients. The differences were significant, especially among the low-risk class, and the occurrence of PDR pathogens was also more frequently observed in HCAP patients than in CAP patients among the low-risk class. These results were similar to the study of Shindo et al. in Japan, which showed higher mortality and PDR pathogens occurrence in HCAP patients than in CAP patients in the moderate severity class according to the A-DROP (age, dehydration, respiratory failure, orientation disturbance, and low blood pressure) scoring system . In patients classified as high-risk, mortality was not different between HCAP and CAP patients, probably due to the severity of the illness itself, regardless of the presence of PDR pathogens. The poorer outcomes for patients with HCAP than for those with CAP in the low-risk class might be explained by the higher rate of early treatment failure (16.4% vs. 6.3%; P = 0.024), associated with a higher proportion of PDR pathogen (41.2% vs. 13.9%; P = 0.027), as shown in Table 4.
Although we could not find a significant difference in the rate of inappropriate initial antibiotics treatment between patients with HCAP and CAP, the proportion of inappropriate antibiotic treatment was significantly higher in HCAP patients infected with PDR pathogen than in those without (58.6% vs. 22.7%; P = 0.002) (data not shown), which is consistent with previous reports [14, 26]. Therefore, it is important to identify risk factors for PDR pathogens in patients with HCAP to decide who should receive broad-spectrum antibiotics. These efforts would improve clinical outcomes and prevent the emergence of multi-drug resistant microorganisms from overuse of broad-spectrum antibiotics. According to multivariate analysis, significant risk factors for PDR pathogens included the use of antibiotics for more than two days during a prior hospitalization within 90 days of pneumonia onset as well as tube feeding. Thus, we suggest that physicians consider broad-spectrum antibiotics for treatment of HCAP patients with these risk factors for PDR pathogens.
HCAP is a newly defined group since 2005 and has been composed of heterogeneous patients with various severities of illness and different reasons for contact with the healthcare environment. Thus, there is little detailed data on these various HCAP groups, though it is associated with significant mortality and high health care costs [27, 28]. This study may provide useful guidance in understanding the characteristics of HCAP and in developing therapeutic approaches for patients with HCAP in South Korea.
To fully appreciate our results, we should consider the limitations of the present study. First, this was a retrospective study in a single institution with a relatively short duration and may not represent South Korean medical institutions in general. However, this study shows the general characteristics of pneumonia patients admitted to tertiary hospitals in South Korea. Second, the etiology of pneumonia was identified in a low proportion of patients. Thus, the true incidence of PDR pathogen and its effects on the clinical outcomes could have been underestimated. However, 89% and 99% of the patients were evaluated using their sputum and blood samples, and our successful pathogen identification rate of 30% was not relatively low compared to the rate of 20-50% from previous prospectively designed studies [10, 29, 30]. Third, atypical pathogens could not be fully evaluated due to inadequate information in the medical records. Fourth, prior antibiotic use could not be fully estimated due to insufficient information from other clinics in the medical records.
In summary, half of the hospitalized with pneumonia in a university tertiary referral hospital were diagnosed with HCAP. Patients with HCAP showed a higher occurrence of PDR pathogens, more frequent early treatment failure, and a higher mortality rate than patients with CAP, especially in patients with low-risk class. Those HCAP patients who underwent tube feeding and those who have been hospitalized and given antibiotic treatment within the previous 90 days should be mainly considered for broad-spectrum antibiotics.
community acquired pneumonia
pneumonia severity index
American Thoracic Society.
Infectious Diseases Society of America
methicillin-resistant Staphylococcus aureus
extended spectrum β-lactamase
microparticle agglutination assay
intensive care unit
The authors are indebted to all who participated in this study. Thanks to all the health care professionals of the Severance Hospital, and specifically those from the pulmonology units and the emergency room.
- Mylotte JM: Nursing home-acquired pneumonia. Clinical Infectious Diseases. 2002, 35 (10): 1205-1211. 10.1086/344281.View ArticlePubMedGoogle Scholar
- Muder RR: Pneumonia in residents of long-term care facilities: epidemiology, etiology, management, and prevention. American Journal of Medicine. 1998, 105 (4): 319-330. 10.1016/S0002-9343(98)00262-9.View ArticlePubMedGoogle Scholar
- Zimmer JG, Hall WJ: Nursing home-acquired pneumonia: avoiding the hospital. Journal of the American Geriatrics Society. 1997, 45 (3): 380-381.View ArticlePubMedGoogle Scholar
- Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL, Reller LB, Sexton DJ: Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Annals of Internal Medicine. 2002, 137 (10): 791-797.View ArticlePubMedGoogle Scholar
- Brito V, Niederman MS: Healthcare-associated pneumonia is a heterogeneous disease, and all patients do not need the same broad-spectrum antibiotic therapy as complex nosocomial pneumonia. Current opinion in infectious diseases. 2009, 22 (3): 316-325. 10.1097/QCO.0b013e328329fa4e.View ArticlePubMedGoogle Scholar
- Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clinical Infectious Diseases. 2000, 31 (2): 383-421. 10.1086/313959.View ArticlePubMedGoogle Scholar
- Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clinical Infectious Diseases. 2003, 37 (11): 1405-1433. 10.1086/380488.View ArticlePubMedGoogle Scholar
- Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. American Journal of Respiratory and Critical Care Medicine. 2001, 163 (7): 1730-1754.View ArticlePubMedGoogle Scholar
- American Thoracic Society/Infectious Diseases Society of America: Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. American Journal of Respiratory and Critical Care Medicine. 2005, 171 (4): 388-416. 10.1164/rccm.200405-644ST.View ArticleGoogle Scholar
- Carratal J, Mykietiuk A, Fernndez-Sab N, Surez C, Dorca J, Verdaguer R, Manresa F, Gudiol F: Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Archives of Internal Medicine. 2007, 167 (13): 1393-1399. 10.1001/archinte.167.13.1393.View ArticleGoogle Scholar
- Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH: Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrobial Agents and Chemotherapy. 2007, 51 (10): 3568-3573. 10.1128/AAC.00851-07.View ArticlePubMedPubMed CentralGoogle Scholar
- Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, Imaizumi K, Sato T, Hasegawa Y: Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009, 135 (3): 633-640. 10.1378/chest.08-1357.View ArticlePubMedGoogle Scholar
- Shorr AF, Zilberberg MD, Micek ST, Kollef MH: Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Archives of Internal Medicine. 2008, 168 (20): 2205-2210. 10.1001/archinte.168.20.2205.View ArticlePubMedGoogle Scholar
- Park HK, Song JU, Um SW, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ, Jeon K: Clinical characteristics of health care-associated pneumonia in a Korean teaching hospital. Respiratory Medicine. 2010, 104 (11): 1729-1735. 10.1016/j.rmed.2010.06.009.View ArticlePubMedGoogle Scholar
- Carratal J, Fernndez-Sab N, Ortega L, Castellsagu X, Rosn B, Dorca J, Fernndez-Agera A, Verdaguer R, Martnez J, Manresa F, Gudiol F: Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients. Annals of Internal Medicine. 2005, 142 (3): 165-172.View ArticleGoogle Scholar
- Trouillet JL, Chastre J, Vuagnat A, Joly-Guillou ML, Combaux D, Dombret MC, Gibert C: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. American Journal of Respiratory and Critical Care Medicine. 1998, 157 (2): 531-539.View ArticlePubMedGoogle Scholar
- Bradford PA: Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clinical Microbiology Reviews. 2001, 14 (4): 933-951, table of contents. 10.1128/CMR.14.4.933-951.2001.View ArticlePubMedPubMed CentralGoogle Scholar
- Menndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A: Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008, 63 (5): 447-452. 10.1136/thx.2007.086785.View ArticleGoogle Scholar
- Rosn B, Carratal J, Fernndez-Sab N, Tubau F, Manresa F, Gudiol F: Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Archives of Internal Medicine. 2004, 164 (5): 502-508. 10.1001/archinte.164.5.502.View ArticleGoogle Scholar
- Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine. 1997, 336 (4): 243-250. 10.1056/NEJM199701233360402.View ArticlePubMedGoogle Scholar
- Yandiola PP, Capelastegui A, Quintana J, Diez R, Gorordo I, Bilbao A, Zalacain R, Menendez R, Torres A: Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest. 2009, 135 (6): 1572-1579. 10.1378/chest.08-2179.View ArticlePubMedGoogle Scholar
- Murray PR, Washington JA: Microscopic and baceriologic analysis of expectorated sputum. Mayo Clinic Proceedings. 1975, 50 (6): 339-344.PubMedGoogle Scholar
- Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptiblity Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. Clinical and Laboratory Standards Institute. 2008, 29 (2): M07-A08.Google Scholar
- Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS: Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005, 128 (6): 3854-3862. 10.1378/chest.128.6.3854.View ArticlePubMedGoogle Scholar
- Niederman MS: Making sense of scoring systems in community acquired pneumonia. Respirology. 2009, 14 (3): 327-335. 10.1111/j.1440-1843.2009.01494.x.View ArticlePubMedGoogle Scholar
- Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Imaizumi K, Hasegawa Y: Comparison of severity scoring systems A-DROP and CURB-65 for community-acquired pneumonia. Respirology. 2008, 13 (5): 731-735. 10.1111/j.1440-1843.2008.01329.x.View ArticlePubMedGoogle Scholar
- Shorr AF, Haque N, Taneja C, Zervos M, Lamerato L, Kothari S, Zilber S, Donabedian S, Perri MB, Spalding J, Oster G: Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010, 48 (9): 3258-3262. 10.1128/JCM.02529-09.View ArticlePubMedPubMed CentralGoogle Scholar
- Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M, Wolkewitz M: Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. Lancet Infect Dis. 2011, 11 (1): 30-38. 10.1016/S1473-3099(10)70258-9.View ArticlePubMedGoogle Scholar
- Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K: Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. European Respiratory Journal. 2008, 32 (1): 139-146. 10.1183/09031936.00092507.View ArticlePubMedGoogle Scholar
- Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A: Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. American Journal of Respiratory and Critical Care Medicine. 1999, 160 (2): 397-405.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2334/11/61/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.